Tanner Becomes First Community Cancer Care Provider to Offer Varian’s HyperSight
Tanner Cancer Care’s newly expanded Roy Richards, Sr. Cancer Center is not only visually impressive but also features the latest advancements in cancer treatment technology. Tanner Cancer Care’s newly expanded…
Pharmanovia In-Licenses Catumaxomab from Lindis Biotech for Malignant Ascites
Pharmanovia, a global pharmaceutical company focused on commercializing innovative medicines and revitalizing established ones, today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab. This…
Study in Heart Rhythm Shows AI Algorithms Cut Alert Burden with PaceMate’s Data Capabilities
A recent study published in Heart Rhythm highlights how artificial intelligence (AI) algorithms embedded in Medtronic’s LINQ II implantable loop recorders (ILRs) significantly reduce alert and episode burdens. This is…
Peek Launches First-Ever ‘Prescription Marketplace’ to Revolutionize Employer Benefits
While every company wants to support their employees’ health, businesses of all sizes face challenges with rising healthcare costs and complex, confusing benefit plans. Prescription medications can be a tough…
Sangamo Therapeutics Gets FDA IND Clearance for ST-503 in Treating Idiopathic Small Fiber Neuropathy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its…
Rocket Pharmaceuticals Publishes Phase 1 RP-A501 Data in NEJM, Presents at AHA Conference 2024
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading biotechnology company focused on developing genetic therapies for rare, life-threatening diseases, announced promising long-term safety and efficacy data from its Phase 1 RP-A501…
Encora Therapeutics Completes ULTRE Trial for Wrist-Worn Essential Tremor Device
Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of…
Vir Biotechnology Announces Positive Chronic Hepatitis Delta Trial Data and Phase 3 Program Launch
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta…
HistoSonics® Enrolls First Patients in BOOMBOX Master Study
HistoSonics, the developer of the Edison® Histotripsy System, has announced the enrollment of the first patients in its novel BOOMBOX study, a prospective master protocol designed to assess the real-world…
Lobe Sciences and Alera Pharma Announce Second U.S. Patent Allowance for Conjugated Psilocin™
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin…
SOLVD Health Launches 5-Year Post-Approval Study on AvertD® Genetic Test
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the…
Supercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI
Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for…